← Back to Search

Sulfur Donor

UW (perfusion solution) + sodium thiosulfate (STS) for Kidney Failure

Phase 1
Waitlist Available
Led By Alp Sener, Dr.
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial will determine if thiosulfate improves kidney function in recipients of deceased donor kidneys.

Eligible Conditions
  • Kidney Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Patient urine output
Patient urine output
Serum Creatinine
+2 more
Secondary study objectives
Biopsy proven Acute tubular necrosis (ATN)
Urinary injury biomarkers (KIM-1/NGAL).
Urine protein/creatinine ratio

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: UW (perfusion solution) + sodium thiosulfate (STS)Active Control1 Intervention
We will flush the deceased donor kidney with UW (perfusion solution) + sodium thiosulfate (STS)
Group II: UW (perfusion solution)Active Control1 Intervention
Kidney will be flushed with UW (perfusion solution) which is the normal standard of care.

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
676 Previous Clinical Trials
416,625 Total Patients Enrolled
2 Trials studying Kidney Failure
41 Patients Enrolled for Kidney Failure
Alp Sener, Dr.Principal InvestigatorLHSC

Media Library

Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25% (Sulfur Donor) Clinical Trial Eligibility Overview. Trial Name: NCT04292184 — Phase 1
Kidney Failure Research Study Groups: UW (perfusion solution) + sodium thiosulfate (STS), UW (perfusion solution)
Kidney Failure Clinical Trial 2023: Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25% Highlights & Side Effects. Trial Name: NCT04292184 — Phase 1
Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25% (Sulfur Donor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04292184 — Phase 1
~4 spots leftby Oct 2025